Cited by 912Fibroblast Growth Factor ResearchAdipose Tissue and MetabolismPeptidase Inhibition and Analysis

Understanding the Physiology of FGF21

Open access
Fisher, Ffolliott Martin, Maratos-Flier, Eleftheria·2016·Annual Review of Physiology

Abstract

Fibroblast growth factor 21 (FGF21) is a peptide hormone that is synthesized by several organs and regulates energy homeostasis. Excitement surrounding this relatively recently identified hormone is based on the documented metabolic beneficial effects of FGF21, which include weight loss and improved glycemia. The biology of FGF21 is intrinsically complicated owing to its diverse metabolic functions in multiple target organs and its ability to act as an autocrine, paracrine, and endocrine factor. In the liver, FGF21 plays an important role in the regulation of fatty acid oxidation both in the fasted state and in mice consuming a high-fat, low-carbohydrate ketogenic diet. FGF21 also regulates fatty acid metabolism in mice consuming a diet that promotes hepatic lipotoxicity. In white adipose tissue (WAT), FGF21 regulates aspects of glucose metabolism, and in susceptible WAT depots, it can cause browning. This peptide is highly expressed in the pancreas, where it appears to play an anti-inflammatory role in experimental pancreatitis. It also has an anti-inflammatory role in cardiac muscle. Although typically not expressed in skeletal muscle, FGF21 is induced in situations of muscle stress, particularly mitochondrial myopathies. FGF21 has been proposed as a novel therapeutic for metabolic complications such as diabetes and fatty liver disease. This review aims to interpret and delineate the ever-expanding complexity of FGF21 physiology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev-physiol-021115-105339

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fisher, F. M., & Maratos-Flier, E.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Department of Medicine, Harvard Medical School, and Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215;
Venue
Annual Review of Physiology
Published
2016-02-10
Volume
78
Issue
1
Pages
223-241
ISSN
  • 0066-4278 (ISSN-L)
  • 1545-1585
OpenAlex
W2132596222
Cited by
912
References
115
Citations by year
2026: 74 · 2025: 120 · 2024: 119 · 2023: 107 · 2022: 97 · 2021: 99 · 2020: 88 · 2019: 80 · 2018: 64 · 2017: 45 · 2016: 19
FWCI
4.13
Type
journal article
Language
en
Open access
Locations
  • Annual Review of Physiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK028082)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Oncology › Peptidase Inhibition and Analysis
Keywords
FGF21, peptide hormones, energy homeostasis, fatty acid oxidation, hepatic lipotoxicity, white adipose tissue browning, glucose metabolism, pancreatitis, cardiac inflammation, mitochondrial myopathy, skeletal muscle, diabetes mellitus, hepatic steatosis, therapeutic target
MeSH terms
Animals, Diabetes Mellitus, Fatty Acids, Fatty Liver, Fibroblast Growth Factors, Homeostasis, Humans, Metabolic Diseases, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review